false
0001566044
0001566044
2024-12-23
2024-12-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 23, 2024
VYNE
Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38356 |
|
45-3757789 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
685
Route 202/206 N., Suite 301
Bridgewater,
New Jersey 08807
(Address of principal executive offices, including
Zip Code)
(800)
775-7936
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common
Stock, $0.0001 par value |
|
VYNE |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On December 23, 2024, VYNE
Therapeutics Inc. (the “Company”) issued a press release entitled “VYNE Therapeutics Reports Positive
Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor.” In addition, on December 23, 2024, the Company posted
a presentation that includes data from its Phase 1a trial of VYN202 on its website.
A copy of the Company’s
press release and presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are
being filed herewith.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
VYNE THERAPEUTICS INC. |
|
|
|
Date: December 23, 2024 |
By: |
/s/ Mutya Harsch |
|
|
Mutya Harsch |
|
|
Chief Legal Officer and General Counsel |
Exhibit 99.1
VYNE Therapeutics
Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
| · | Promising
results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders |
| · | Consistent
with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically
associated with earlier generation, less selective BET inhibitors |
| · | VYN202
demonstrated robust pharmacodynamic activity including evidence of target engagement and significant inhibition of inflammatory biomarkers
relevant to several immune-mediated disorders in ex vivo stimulation assays |
BRIDGEWATER, NJ, December 23, 2024 -- VYNE Therapeutics
Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing
differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive results
from the multiple ascending dose (“MAD”) portion of its Phase 1a SAD/MAD trial of VYN202. The Phase 1a trial was a two-part,
double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of single ascending dose (“SAD”) and
MAD components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202.
Key Findings from the Top-line Phase 1a MAD
Results for VYN202:
| · | VYN202 demonstrated a favorable safety and tolerability
profile with no drug-related adverse events historically associated with earlier generation, less selective bromodomain and extra-terminal
domain (“BET”) inhibitors, including thrombocytopenia, neutropenia or gastrointestinal toxicity findings |
| · | No
serious adverse events (AEs), discontinuations due to an AE or clinically meaningful treatment emergent adverse events (TEAEs). All TEAEs
were considered mild or moderate in severity. |
| · | No
drug-related adverse events associated with laboratory results. There were no AEs of any severity grade relating to thrombocytopenia,
which is a known dose-limiting toxicity associated with earlier generations of BET inhibitors. |
| · | Favorable PK profile demonstrated for VYN202: |
| · | Data
supports once-daily dosing regimen. |
| · | VYN202
demonstrated dose dependent exposure that reached steady-state after 7 once-daily doses. |
| · | VYN202
blood levels were within key inhibitory thresholds of IC50 to IC90 against BD2 BRD4 for at least 24 hours at all doses. |
| · | No
drug-drug interaction was observed when VYN202 was co-administered with methotrexate, a treatment commonly used in the management of
chronic immuno-inflammatory conditions. |
| · | VYN202 demonstrated robust pharmacodynamic activity
on target engagement and inflammatory biomarkers in ex vivo assays: |
| · | VYN202
induced a dose-dependent increase in the target engagement biomarker HEXIM-11 with a maximal effect observed at 0.5mg to 1.0
mg QD. |
| · | VYN202
inhibited the production of multiple inflammatory biomarkers related to Th17, Th1/myeloid and Th1/Tc dysregulated activity, consistent
with preclinical models of VYN202. |
“We are very excited by the PK, pharmacodynamic
and safety data generated in this trial which not only support the further development of VYN202 but also give us increased confidence
that VYN202 has the potential to become a novel treatment option for immune-mediated diseases,” said David Domzalski, President
and Chief Executive Officer of VYNE. “VYN202 has been designed to address the adverse events that have been historically associated
with early generation BET inhibitors. We believe the data from this Phase 1a SAD/MAD trial validates our drug design thesis for VYN202.
Based on these positive results, we look forward to finalizing our clinical trial plans for VYN202 in patients over a longer duration
of treatment.”
For more information on the Phase 1a trial
results, please visit the investor section of VYNE’s website.
About the MAD Portion of the Phase 1a Trial
The MAD portion of the trial was designed to evaluate
multiple ascending doses of VYN202 given to healthy volunteers for 14 days. Four study cohorts evaluated VYN202 dosed at 0.5mg QOD, 0.5mg
QD, 1mg QD and 1mg QD in combination with methotrexate 7.5mg QWK. The 0.5mg QOD cohort was intended to approximate 0.25mg QD dosing and
the methotrexate combination cohort evaluated potential drug-drug interactions with methotrexate, a treatment commonly used in the management
of chronic inflammatory conditions.
The trial evaluated safety, tolerability, PK and
exploratory pharmacodynamics of VYN202. Participant blood samples were stimulated ex-vivo to assess the pharmacodynamic impact of VYN202
on target engagement and inflammatory biomarkers.
About VYN202
VYN202 is an innovative, oral small molecule BET
inhibitor that has potential class-leading selectivity and potency for BD2 vs. BD1. By maximizing BD2 selectivity, VYNE believes VYN202
has the potential to be a differentiated, more conveniently administered non-biologic treatment option for both acute control and chronic
management of immuno-inflammatory indications, in which the damaging effects of unrestricted inflammatory signaling activity is common.
VYN202 is structurally distinct from VYNE’s pan-BET inhibitor (VYN201) and covered by distinct Patent Cooperation Treaty and provisional
composition of matter patent applications directed to new chemical entities and their uses.
About BET Inhibitors
BET proteins play a key role in regulating gene
transcription via epigenetic interactions (“reading”). Recent research has identified a key role for these proteins in regulating
activation of immune cells, including T and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers, BET proteins
regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines. BET inhibitors
have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine transcription,
with additional potential in myeloproliferative neoplastic disorders.
1 Lin, Xiaoyu et al. “HEXIM1
as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.”
Molecular Cancer Therapeutics vol. 16,2 (2017): 388-396. doi:10.1158/1535-7163.MCT-16-0475.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company
focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's
unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation
BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.
For more information about VYNE Therapeutics
Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations
under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with
the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical
development of VYNE’s product candidates, including VYN202, the potential benefits of VYNE’s product candidates, including
VYN202, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which
are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and
its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could
cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of
commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results
from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through equity or debt financing
transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For
a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ
from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report
on Form 10-K for the year ended December 31, 2023, and VYNE’s other filings from time to time with the U.S. Securities and Exchange
Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement
and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except
as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions
of future events.
Third-party products and company names mentioned herein may be the
trademarks of their respective owners.
Exhibit 99.2

VYN202 P1a SAD/MAD Data December 2024

Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc . (“VYNE”) includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE’s development plans and timelines for VYN 201 and VYN 202 , VYNE’s InhiBET platform, planned trial designs, potential market opportunities, VYNE's cash runway and other statements regarding the future expectations, plans and prospects of VYNE . All statements in this presentation which are not historical facts are forward - looking statements . Any forward - looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward - looking statements . These risks and uncertainties include, but are not limited to : VYNE’s ability to successfully develop its product candidates ; the timing of commencement of future preclinical studies and clinical trials ; VYNE’s ability to enroll patients and successfully progress, complete, and receive favorable results from, clinical trials of its product candidates ; VYNE’s ability to comply with various regulations applicable to its business ; VYNE’s ability to create intellectual property and the scope of protection it is able to establish and maintain for intellectual property rights covering its product candidates, including the projected terms of patent protection ; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent applications ; estimates of VYNE’s expenses and capital requirements, and its ability to obtain additional capital on acceptable terms or at all ; VYNE’s expectations regarding licensing, business transactions and strategic operations ; VYNE’s future financial performance and liquidity ; and volatility in VYNE’s stock price may result in rapid and substantial increases or decreases in the stock price that may or may not be related to VYNE’s operating performance or prospects . For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward - looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10 - K for the year ended December 31 , 2023 , as well as discussions of potential risks, uncertainties, and other important factors in VYNE’s subsequent filings with the U . S . Securities and Exchange Commission . Although VYNE believes these forward - looking statements are reasonable, they speak only as of the date of this presentation and VYNE undertakes no obligation to update publicly such forward - looking statements to reflect subsequent events or circumstances, except as otherwise required by law . Given these risks and uncertainties, you should not rely upon forward - looking statements as predictions of future events . Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third - party sources and VYNE’s own internal estimates and research . While VYNE believes these third - party sources to be reliable as of the date of this presentation, VYNE has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources . In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions . Finally, while VYNE believes its own internal research is reliable, such research has not been verified by any independent source . You are cautioned not to give undue weight to any such information, projections and estimates . The trademarks included herein are the property of the owners thereof and are used for reference purposes only . This presentation concerns product candidates that are under clinical investigation . None of such product candidates have been approved for marketing by the FDA or the EMA, and such product candidates are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated . 2

3 BET Proteins: Key Epigenetic Regulators of NF - kB, a Master Orchestrator of Inflammation Indication Cell type / Cytokine pathway Vitiligo , Lichen Planus, Alopecia Areata Th1/Tc1 IL - 12, IFN , BATF Psoriasis , PsA, IBD Th17 IL - 17, IL - 23, IL - 21, RORC Autoantibody - mediated diseases (e.g., SLE, RA) Tfh IL - 21 Autoantibody - mediated diseases (e.g., SLE, RA) B cells BAFF, IL - 21, IL - 19, IL - 22 RA , psoriasis , PsA, IBD, Axial SpA , HS Myeloid cells TNF, IL - 6, IL - 1, chemokines, adhesion molecules Adapted from Wang, N., Wu, R., Tang, D. et al. The BET family in immunity and disease (2021)

VYN202: A Novel BD2 - Selective BET Inhibitor for Immune - Mediated Diseases 4 1. Based on readily available public information such as clintrials.gov, academic publications and corporate websites/present ati ons. • VYN202 is an innovative, oral BD2 - Selective BET inhibitor • VYN202 is believed to be the most potent and BD2 - selective BET Inhibitor in clinical development 1 which is designed to improve efficacy and tolerability • VYN202 has demonstrated a significant inhibitory effect on key disease - related inflammatory biomarkers that correspond with reduced disease severity observed across multiple diverse preclinical models of autoimmune disease • Phase 1 SAD and MAD studies in healthy volunteers complete: • VYN202 was generally well tolerated with no drug - related adverse events historically associated with earlier generation, less selective BET inhibitors • Favorable PK profile demonstrated for VYN202, supporting once - daily dosing regimen • VYN202 demonstrated robust pharmacodynamic activity including evidence of target engagement and significant inhibition of inflammatory biomarkers relevant to several immune - mediated disorders in ex vivo stimulation assays Compelling data support VYN202’s potential as a novel, once - daily oral treatment for a broad range of immune - mediated disorders

Maximizing On - target Potency vs. BD2 and Minimizing Affinity to BD1 May B e T he Key to Optimizing the Benefit/Risk Profile of BET Inhibitors for Autoimmune Diseases 5 Selectivity ** (BD1/BD2) Potency vs. BD2 * ( nM ) Compound ID ~10,000 1 VYN202 (VYNE) 1,460x (FRET) 2 NUV - 868 ( Nuvation ) 2 753x (FRET) 28 ABBV - 744 (AbbVie) 3 220x 79 GSK620 (GSK) 4 5x (FRET) 17 Pelabresib (NVS/MOR) 2 2.6x 13 ABBV - 075 3 1.5x 26 MK - 8628/OTX - 015 5 0.1x 41 BI - 894999 6 *Lower number denotes higher potency **Higher number denotes higher selectivity. Data based on nanoBRET assay unless otherwise indicated. 1. Based on readily available public information such as clintrials.gov, academic publications and corporate websites/present ati ons. 2. Nuvation corporate presentation (August 2024); 3. Faivre et al 2020; 4. Delmont et al 2020; 5. Wang et al 2017 6. Kraut et al 2018; Data on file VYN202 is believed to be the most potent and BD2 - selective BET Inhibitor in clinical development 1 which is designed to improve efficacy and tolerability BD1 BD2 EXT BD2 activity is associated with inflammatory gene induction that drives inflammatory responses in autoimmune disease BD1 regulates “housekeeping” gene activity

- 10 20 30 40 50 60 70 80 IL-17 IL-22 VYN202: Clinical and Biomarker Effects Comparable to Deucravacitinib in Preclinical in vivo Model of Psoriasis 6 Day 15 After 7 days of treatment IMI/VYN202 3mg/kg IMI/Placebo IMI/Deucravacitinib 3mg/kg - 5 10 15 IL - 1 β IL-6 TNF - α IL-23 >93% lower expression of IL - 17 in blood at all VYN202 doses compared to placebo Marked reduction of other disease related Th17 and Th1 cytokines in blood Pg/ml >93% lower expression of IL - 17 for VYN202 vs. Placebo Pg/ml 0 25 50 75 100 125 150 8 9 10 11 12 13 14 15 Post - induction Treatment Day % Change in PASI Score VYN202 and Deucravacitinib surpassed PASI - 90 by day 7 of treatment 1Sotyktu® ( deucravacitinib ) was approved in the U.S. in September 2022.; PASI - 90 = 90% improvement from baseline in PASI score; Dorsal depilated BALB - C mice were dosed for 14 days with topical IMI cream (Day 1 - 7: induction phase, Day 8 - 14: treatment phase) ; IMI = imiquimod IMI/Placebo IMI/VYN202 (1mg/kg) IMI/VYN202 (3mg /kg) IMI/VYN202 (10mg /kg) IMI/ Deucra (3mg /kg)

VYN202: Anti - Arthritic Effect and Decreased Antibody Levels Demonstrated in Preclinical Models of Arthritis, including a Comparable Effect to Upadacitinib 7 79% >98% lower expression of anti - CII IgG1 vs. CIA+placebo Collagen - Induced Arthritis Model Adjuvant - Induced Arthritis Model *: P<0.05 **: p<0.01 ** ** ** * * • VYN202’s increased potency and selectivity led to improved outcomes vs. early generation BET inhibitor, GSK620 • VYN202 treatment resulted in dose - dependent reduction in severity of histopathology scores; Statistically superior to Placebo and GSK620 • Comparable effect on paw volume and IgG1 expression to Upadacitinib • Histopathology scores showed significant effect on preventing ankle inflammation vs. control for VYN202 10mpk (67% reduction vs. control) and Upadacitinib 10mpk (56% reduction vs. control) 88 % 1Histopathology data on file

8 VYN202 Results Show Strong Correlation with VYN201 Results Reinforcing BET potential and role of BD2 inhibition in treatment of autoimmune diseases 0 10 20 30 40 50 60 70 80 90 100 % Improvement from Baseline at Day 15 Psoriasis Model VYN201 Locally - administered 0.01% 0.1% 1% 1 (mg/kg) 3 10 3 VYN202 Deucra 71% 0 1 2 3 4 0 3 4 5 6 7 8 10 12 Clinical score treated leg 69% VYN201 - Locally - administered VYN202 Psoriasis Model Arthritis Model (CIA)

VYN202: Phase 1a SAD/MAD Data

VYN202 Phase 1a SAD/MAD Trial Design and Key Objectives 10 Placebo - controlled study evaluating safety, tolerability, PK and PD First - in - human trial in healthy volunteers complete 1. Intended to approximate 0.25mg QD dosing; DDI = drug - drug interaction Assess: Safety, Tolerability, Exposure Exploratory ex vivo pharmacodynamic data: • Target engagement • Inflammatory biomarker and cytokine panel Key Objectives Healthy Volunteers SAD MAD Trial size: N=40 Evaluated 4 doses of VYN202 (N=8 / cohort: 6 active : 2 placebo) 4 mg 2 mg 1 mg Complete Trial size: N=32 Evaluated 3 doses of VYN202 for 14 days and DDI with methotrexate (N=8 / cohort: 6 active : 2 placebo) 1 mg QD + MTX 1 mg QD 0.5 mg QD 1 mg Food Effect 0.5 mg QOD 1 0.5 mg

VYN202 Demonstrated a Favorable Safety and Tolerability Profile in Phase 1 11 VYN202 was generally well tolerated in Phase 1 MAD with no drug related AEs of special interest historically associated with BET inhibitor class VYN202 Placebo (n=6) Treatment Emergent AEs Number of Subjects Reporting (%) 1 mg QD (n=6) 0.5 mg QD (n=6) 0.5 mg QOD (n=6) 3 (50.0) 2 (33.3) Constipation 1 (16.7) 1 (16.7) Drowsiness 1 (16.7) 1 (16.7) Dysmenorrhea 1 (16.7) 1 (16.7) Headache 1 (16.7) 1 (16.7) Pruritus Note: Reported in >1 subject. Excludes those associated with ECG electrode placement and venipuncture reaction • VYN202 was generally well tolerated • No serious adverse events or discontinuations due to an AE • No clinically meaningful treatment emergent AEs • All treatment emergent AEs considered mild or moderate • No clinically significant abnormalities in clinical labs or electrocardiogram • No drug related AEs of special interest historically associated with the BET inhibitor class (thrombocytopenia, neutropenia o r g astrointestinal safety findings) Safety Findings MAD Results

VYN202 Phase 1 MAD Results: Selected Laboratory Data 12 All laboratory results within normal limits throughout treatment and follow - up period 0 100 200 300 400 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean 10^3/ uL ( “ SE) Day 20 25 30 35 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean seconds ( “ SE) Day 0.0 1.0 2.0 3.0 4.0 5.0 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean 10^3/ uL ( “ SE) Day 0 5 10 15 20 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean g/dL ( “ SE) Day Platelets Neutrophils Lymphocytes Cholesterol Hemoglobin aPTT Placebo (n=6) 0.5 mg QOD (n=6) 0.5 mg QD (n=6) 1.0 mg QD (n=6) Upper/Lower limit of normal PD=Pre - dose Grade 1 (<150 - 75) Grade 2 (75 - 50) 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean 10^3/ uL ( “ SE) Day Grade 4 (0 - 25) Grade 3 (50 - 25) 0 100 200 300 400 PD 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Mean mg/dL ( “ SE) Day

VYN202 Phase 1 SAD and Day 14 MAD Pharmacokinetics 13 • Dose - dependent exposure from dose 0.5 QOD to 4mg, with low variability • ~ 4 - fold accumulation observed, steady state reached after 7 QD doses • VYN202 exposure remained above key inhibitory levels vs. BD2 BRD4 for 24 hours post - dose on Day 14 • Median half - life of 36 - 41 hours supports a once daily dosing posology • No drug - drug interaction with methotrexate • Increased exposure with high fat diet 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 0 4 8 12 16 20 24 Mean ( “ SEM) Concentration (ng/mL) Time (Hours) 1mg QD 0.5mg QD 0.5mg QOD 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 0 4 8 12 16 20 24 Mean ( “ SEM) Concentration (ng/mL ) Time (Hours) 4.0mg QD 2.0mg QD 1mg QD 0.5mg QD IC50 IC90 Mean Time Above IC vs. BD2 at Day 14 ( hr ) IC75 IC50 Dose >24 >24 1 mg QD ~8 >24 0.5 mg QD 0 >24 0.5 mg QOD IC determined vs. BD2 BRD4 from cell - based nano - BRET assay IC50 IC90 IC75 IC75 Single Ascending Dose PK Multiple Ascending Dose PK, Day 14

Pharmacokinetics Show Strong Correlation with Target Engagement 14 • Inhibition of BET proteins release pTEFb * which activates transcription of pTEFb - dependent genes such as HEXIM - 1 leading to higher expression of the HEXIM - 1 protein • Induction of HEXIM - 1 closely follows corresponding pharmacokinetics of VYN202 ( Tmax : ~4hrs) 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 0 4 8 12 16 20 24 Mean ( “ SEM) Concentration (ng/mL) Time (Hours) 1mg QD 0.5mg QD 0.5mg QOD IC50 IC90 pTEFb : positive transcription elongation factor - b IC75 Multiple Ascending Dose PK, Day 14 Multiple Ascending Dose HEXIM - 1 Induction, Day 14 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 0 4 8 12 16 20 24 Mean ( “ SEM) Fold Induction vs. Predose Time (Hours) 0.5mg QOD 0.5mg QD 1.0mg QD Placebo Dose - dependent induction of HEXIM - 1 with maximum effect observed at 0.5 - 1.0mg QD

Demonstrated Impact on Pro - Inflammatory and Disease Related Cytokines 15 -60% -50% -40% -30% -20% -10% 0% 10% 20% 30% 40% Mean % Change from Baseline Ex Vivo Inhibition of Disease Related Cytokines 1 , Day 14 1U sing TLR4/TLR7 stimulation and analysis from whole blood samples Th1/Tc1 Th1/Myeloid Cells Th17 CXCL10 (%) IFN γ (%) IL - 6 (%) TNF (%) IL - 1 β (%) IL - 23 (%) IL - 17 (%) cytokines 27 6 5 27 18 30 31 Placebo (n=6) - 37 - 47 - 29 - 45 - 16 - 33 - 12 0.5mg QOD (n=6) - 47 - 52 - 37 - 34 - 33 - 51 - 29 0.5mg QD (n=6) - 47 - 56 - 44 - 38 - 16 - 27 - 42 1.0mg QD (n=6) - 74 - 62 - 49 - 72 - 51 - 81 - 73 Max Δ vs placebo Significant inhibition of key cytokines relevant to several autoimmune diseases Comparable inhibitory effects to that demonstrated in preclinical efficacy models Emerging relationship between VYN202 exposure, HEXIM - 1 induction and cytokine inhibition

Majority of Cytokine Suppression Occurs in Concentrations at 1mg or Below 16 in preclinical in vitro tests at fixed concentrations of VYN202 ranging from 0 to 10 ng/mL 1. 0.5mg QOD intended to approximate 0.25mg QD dose 2. Mean clinical concentration range of VYN202 is approximately 0.5 ng/mL (0.5mg QOD trough concentration at steady state) to approximately 5 ng/mL (1mg Cmax at steady state). -100 -75 -50 -25 0 0 1 2 3 4 5 6 7 8 9 10 % Inhibition IFN TNF IL23 IL17 IL1 β IL6 - IC50 BD2 BRD4 - IC90 BD2 BRD4 VYN202 clinical exposure range (0.5 QOD - 1mg QD) VYN202 Concentration in Whole Blood (ng/mL) VYN202 exhibited steep exposure/response curves, consistent with preclinical disease models Majority of inhibitory effect occurs at exposures equivalent to 0.25mg QD 1 to 1mg QD dosing of VYN202 (0 to 5 ng/mL) Minimal additional inhibitory benefit with increased exposure beyond 5ng/mL

VYN202 Phase 1a MAD Data Summary 17 • Demonstrated favorable safety and tolerability profile • No drug - related adverse events historically associated with earlier generation, less selective BET inhibitors, including thrombocytopenia, neutropenia or gastrointestinal toxicity findings • No serious adverse events (AEs), discontinuations due to an AE or clinically meaningful treatment emergent adverse events (TEAEs) • All TEAEs were considered mild or moderate in severity • No drug - related adverse events associated with laboratory results • There were no AEs of any severity grade relating to thrombocytopenia, which is a known dose - limiting toxicity associated with earlier generations of BET inhibitors Safety Pharmacokinetics • Favorable PK profile • Data supports once - daily dosing regimen • VYN202 demonstrated dose dependent exposure that reached steady - state after 7 once - daily doses • VYN202 blood levels were within key inhibitory thresholds of IC50 to IC90 against BD2 BRD4 for at least 24 hours at all doses • No drug - drug interaction observed when VYN202 was co - administered with methotrexate, a treatment commonly used in the management of chronic immuno - inflammatory conditions Pharmacodynamics • Robust pharmacodynamic activity on target engagement and inflammatory biomarkers in ex vivo assays • VYN202 induced a dose - dependent increase in the target engagement biomarker HEXIM - 1 with a maximal effect observed at 0.5mg to 1.0 mg QD • VYN202 inhibited the production of multiple inflammatory biomarkers related to Th17, Th1/myeloid and Th1/Tc dysregulated activity, consistent with preclinical models of VYN202 • VYN202 exhibited steep exposure/response curves, consistent with preclinical disease models, with majority of inhibitory effect occurring at exposures equivalent to 0.25mg QD to 1mg QD dosing of VYN202 (0 to 5 ng/mL) Compelling data support VYN202’s potential as a novel, once - daily oral treatment for a broad range of immune - mediated disorders
v3.24.4
Cover
|
Dec. 23, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 23, 2024
|
Entity File Number |
001-38356
|
Entity Registrant Name |
VYNE
Therapeutics Inc.
|
Entity Central Index Key |
0001566044
|
Entity Tax Identification Number |
45-3757789
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
685
Route 202/206 N.
|
Entity Address, Address Line Two |
Suite 301
|
Entity Address, City or Town |
Bridgewater,
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08807
|
City Area Code |
800
|
Local Phone Number |
775-7936
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value
|
Trading Symbol |
VYNE
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
VYNE Therapeutics (NASDAQ:VYNE)
過去 株価チャート
から 1 2025 まで 2 2025
VYNE Therapeutics (NASDAQ:VYNE)
過去 株価チャート
から 2 2024 まで 2 2025